Trivitron COVID-19 kits ensure detection of SARS-CoV-2 and its other mutated variants including Omicron
New Delhi, 2nd December 2021: COVID-19 variants have profoundly changed the trajectory of the pandemic across the world. It is important to get tested to reduce risk due to concerns like the coronavirus's infectious nature,
New Delhi, 2nd December 2021: COVID-19 variants have profoundly changed the trajectory of the pandemic across the world. It is important to get tested to reduce risk due to concerns like the coronavirus’s infectious nature, immune system evasion and vaccine resistance. The new strain Omicron has been detected in more than 30 countries and is spreading at a fast pace.
Trivitron’s R&D team is monitoring the in-silico analysis of mutation of the COVID-19 virus, to ensure that Trivitron’s COVID-19 Testing kits can effectively detect the mutated strain variants, Omicron. The new strain Omicron contains mutations in its Spike (S) protein and our in-silico analysis suggests that none of the mutations associated with this variant impact Trivitron COVID-19 test kits to detect the novel strain, as they do not rely on the spike gene-based detection.
Trivitron Healthcare manufactures COVID-19 Rapid Antigen Test Kit and COVID-19 RT- PCR Test Kits, which are highly sensitive & specific and are effective in detecting new strains. Wide range of literature and our in-silico analysis suggests these kits can detect conserved regions of the coronavirus RNA and can detect a varied range of COVID-19 infection variants like Omicron, Beta, Zeta, Epsilon, Delta, Kappa, Gamma, Lambda, and many more.
Trivitron COVIDSure and COVIDSure PRO RT-PCR Kits detect the conserved region of SARS-CoV-2 and ORF1ab, Envelope E-gene, and Nucleocapsid N-gene. Mutation in S gene associated with Omicron and other variants remains un-affected by this multiplex RT-PCR test. These kits can detect SARS-COV-2 variants including Omicron.
Trivitron BIOCARD Pro COVID-19 Rapid Antigen Kit is an immunochromatography based test that offers qualitative detection of specific antigens to COVID-19 present in the human nasopharyngeal swab. This antigen test kit detects the conserved region of SARS-CoV-2 that remains unaffected by the mutation in the S gene, hence can detect the Omicron variant of coronavirus.
This new strain is potentially more contagious than previous variants and has thrown a big spotlight over the world. Trivitron’s top priority remains to make tests accessible, quick, effective and available to those who need them most. Trivitron R&D team, scientists and quality control department verify the tests by continuous literature review and in-silico analysis of the new circulating strains keeping in track the importance of effective and precise diagnosis for the masses.
About Trivitron Healthcare:
Since 1997, the journey of Trivitron Healthcare as a medical technology company providing affordable healthcare solutions weaves a fascinating thread of inspiration to many healthcare providers. Having a solid expertise in research and development, Trivitron manufactures and distributes exceptional medical technology products to 180 countries. With 13 certified manufacturing facilities in India, Finland, Turkey & China; Trivitron spearheads innovation in the fields of COVID-19 Products, In-Vitro Diagnostics, Imaging & Radiology, Radiation Protection, Newborn Screening, Critical Care and Operating Room Solutions, thus, engraving its name as a holistic healthcare provider.
